Loading clinical trials...
Loading clinical trials...
The UroDNA study is a feasibility study (RIPH category 3) aimed at evaluating the analysis of circulating tumour DNA in urine (urinary cfDNA) as a non-invasive monitoring tool in patients with prostat...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Institut Cancerologie de l'Ouest
NCT07580196 · Prostate Cancer
NCT06787053 · Bladder (Urothelial, Transitional Cell) Cancer, Prostate Cancer
NCT06616155 · Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, and more
NCT07124000 · Adenocarcinoma (NOS), Anal Cancer, and more
NCT06682728 · Urothelial Carcinoma, Muscle-invasive Bladder Cancer
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions